- 专利标题： FCRN ANTAGONISTS AND METHODS OF USE
-
申请号： EP19189186.0申请日： 2014-12-23
-
公开(公告)号： EP3626738A1公开(公告)日： 2020-03-25
- 发明人: ULRICHTS, Peter , BLANCHETOT, Christophe , DREIER, Torsten , DE HAARD, Johannes , WARD OBER, E., Sally , ONGENAE, Nicolas G.H.
- 申请人： Argenx BVBA , The Board of Regents of the University of Texas System
- 申请人地址： Industriepark 7 9052 Zwijnaarde BE
- 专利权人： Argenx BVBA,The Board of Regents of the University of Texas System
- 当前专利权人： Argenx BVBA,The Board of Regents of the University of Texas System
- 当前专利权人地址： Industriepark 7 9052 Zwijnaarde BE
- 代理机构： Boult Wade Tennant LLP
- 优先权： US201361920547P 20131224
- 主分类号： C07K16/00
- IPC分类号： C07K16/00 ; A61K38/00 ; A61K38/17
摘要：
Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
信息查询
